Jennifer HTD. PharmD Le
Research Subjects
Jennifer HTD. PharmD Le has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Aamir Md Qureshi
Galderma Laboratories, L.P., Dallas, Texas
1 shared publicationAlan Mbbch Widgerow
ALASTIN, a Galderma Company, Carlsbad, California
1 shared publicationDaniel Brasater
Galderma, Uppsala, Sweden
1 shared publication- Daniel Bråsäter
Galderma, Uppsala, Sweden
1 shared publication Edwige Nicodeme
Galderma, Lausanne, Switzerland
1 shared publication- Inna Prygova
Galderma, Uppsala, Sweden
1 shared publication
Latest Publications
- Open Access
- 18 May 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (6S) , S10-S15
Poly-l-Lactic Acid as a Regenerative Treatment for the Glucagon-like Peptide-1 Receptor Agonist User Population
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) used for weight management have introduced unintended facial changes only partially addressed by conventional volumizing fillers. OBJECTIVE: Evaluate the mechanistic rationale and clinical evidence supporting poly- l -lactic acid Sculptra (PLLA-SCA) as a biostimulatory and regenerative treatment for GLP-1 RA–associated facial changes. METHODS: This narrative review synthesizes mechanistic and clinical data alongside expert opinion regarding PLLA-SCA for GLP-1 RA–driven weight loss, focusing on its biostimulatory and regenerative effects across skin layers. RESULTS: Poly- l -lactic acid Sculptra induces fibroblast recruitment and stimulates regeneration of collagen and elastin, and effects vasculature and adipose tissue, resulting in durable improvements in skin quality, elasticity, facial contour, and perceived age that persist for 2 years or longer. Clinical studies and real-world experiences demonstrate clinically meaningful corrections of midface and perioral volume loss, jawline contour, and radiance, including in patients with GLP-1 RA–related facial changes. CONCLUSION: Poly- l -lactic acid Sculptra may help address GLP-1 RA–associated facial atrophy by supporting long-term regeneration and restoration of facial definition, contour, and skin quality. The effects potentially extend across all 3 skin layers affected by the GLP-1 RA phenotype, including atrophy and gauntness. Poly-L-lactic acid Sculptra offers clinicians an option to deliver durable regenerative treatment that helps restore facial aesthetics in this patient population.
- 18 May 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (6S) , S10-S15
Open AccessPoly-l-Lactic Acid as a Regenerative Treatment for the Glucagon-like Peptide-1 Receptor Agonist User Population
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) used for weight management have introduced unintended facial changes only partially addressed by conventional volumizing fillers. OBJECTIVE: Evaluate the mechanistic rationale and clinical evidence supporting poly- l -lactic acid Sculptra (PLLA-SCA) as a biostimulatory and regenerative treatment for GLP-1 RA–associated facial changes. METHODS: This narrative review synthesizes mechanistic and clinical data alongside expert opinion regarding PLLA-SCA for GLP-1 RA–driven weight loss, focusing on its biostimulatory and regenerative effects across skin layers. RESULTS: Poly- l -lactic acid Sculptra induces fibroblast recruitment and stimulates regeneration of collagen and elastin, and effects vasculature and adipose tissue, resulting in durable improvements in skin quality, elasticity, facial contour, and perceived age that persist for 2 years or longer. Clinical studies and real-world experiences demonstrate clinically meaningful corrections of midface and perioral volume loss, jawline contour, and radiance, including in patients with GLP-1 RA–related facial changes. CONCLUSION: Poly- l -lactic acid Sculptra may help address GLP-1 RA–associated facial atrophy by supporting long-term regeneration and restoration of facial definition, contour, and skin quality. The effects potentially extend across all 3 skin layers affected by the GLP-1 RA phenotype, including atrophy and gauntness. Poly-L-lactic acid Sculptra offers clinicians an option to deliver durable regenerative treatment that helps restore facial aesthetics in this patient population.
- Top Cited PapersOpen Access
- 17 November 2025
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal
- Vol. 46 (5) , 509-519
A Multicenter, Open-Label Study of Combined Poly-L-Lactic Acid and Hyaluronic Midface Filler Regimen Enhances Facial Harmony and Skin Quality in GLP-1 Medication Users
Background: Weight loss induced by glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to facial volume loss, wrinkles, and sagging skin, resulting in an aged and gaunt appearance that negatively affects subject satisfaction and self-perception. Objectives: This study assessed the treatment regimen of poly-L-lactic acid (PLLA-SCA) and 2 hyaluronic acid midface fillers (HA-LYF, HA-CON) on restoring facial balance, correcting contour deficiencies, and improving skin quality in subjects who experienced weight loss from GLP-1 RA therapy. Methods: This multicenter, open-label study enrolled 41 subjects with cheek wrinkles and midface contour deficiencies following GLP-1 RA–driven weight loss. Subjects received 2 to 3 treatment sessions of PLLA-SCA and 1 to 2 treatment sessions of HA-LYF or HA-CON, with follow-ups through 9 months since the last PLLA-SCA treatment. Efficacy evaluations included objective skin quality assessments using bioinstrumentation, improvements in facial contour deficiencies using standardized photography, and subject self-assessment questionnaires. Safety was also monitored throughout the study. Results: The PLLA-SCA and HA-LYF or HA-CON treatment regimen significantly improved facial skin quality and enhanced contour in the cheek, jawline, and perioral areas, and demonstrated objective improvement in hydration and skin radiance. Additionally, subjects were satisfied with the treatment results, with no treatment-related adverse events reported. Conclusions: PLLA-SCA and HA-LYF or HA-CON provided effective, safe, and sustained improvements in facial balance, contour, and skin quality in subjects who experienced facial volume loss and ageing from weight loss following GLP-1 RA therapy. Level of Evidence: 3 (Therapeutic):
- 17 November 2025
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal
- Vol. 46 (5) , 509-519
Top Cited PapersOpen AccessA Multicenter, Open-Label Study of Combined Poly-L-Lactic Acid and Hyaluronic Midface Filler Regimen Enhances Facial Harmony and Skin Quality in GLP-1 Medication Users
Background: Weight loss induced by glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to facial volume loss, wrinkles, and sagging skin, resulting in an aged and gaunt appearance that negatively affects subject satisfaction and self-perception. Objectives: This study assessed the treatment regimen of poly-L-lactic acid (PLLA-SCA) and 2 hyaluronic acid midface fillers (HA-LYF, HA-CON) on restoring facial balance, correcting contour deficiencies, and improving skin quality in subjects who experienced weight loss from GLP-1 RA therapy. Methods: This multicenter, open-label study enrolled 41 subjects with cheek wrinkles and midface contour deficiencies following GLP-1 RA–driven weight loss. Subjects received 2 to 3 treatment sessions of PLLA-SCA and 1 to 2 treatment sessions of HA-LYF or HA-CON, with follow-ups through 9 months since the last PLLA-SCA treatment. Efficacy evaluations included objective skin quality assessments using bioinstrumentation, improvements in facial contour deficiencies using standardized photography, and subject self-assessment questionnaires. Safety was also monitored throughout the study. Results: The PLLA-SCA and HA-LYF or HA-CON treatment regimen significantly improved facial skin quality and enhanced contour in the cheek, jawline, and perioral areas, and demonstrated objective improvement in hydration and skin radiance. Additionally, subjects were satisfied with the treatment results, with no treatment-related adverse events reported. Conclusions: PLLA-SCA and HA-LYF or HA-CON provided effective, safe, and sustained improvements in facial balance, contour, and skin quality in subjects who experienced facial volume loss and ageing from weight loss following GLP-1 RA therapy. Level of Evidence: 3 (Therapeutic):
- 1 November 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 50 (11S) , S166-S171
Comparative Bulk RNA-Seq Analysis of Poly-l-Lactic Acid Versus Calcium Hydroxylapatite Reveals a Novel, Adipocyte-Mediated Regenerative Mechanism of Action Unique to PLLA
BACKGROUND: Injectable biostimulators are widely used to improve facial aging signs. This study was performed to compare the genetic pathways affected by 2 different injectable biostimulators. METHODS: Randomized 13-week study (n = 21) comparing gene expression after poly l-lactic acid (PLLA-SCA) and calcium hydroxylapatite (CaHA-R) injections (baseline [BL] and Day 28) as treatment of nasolabial fold wrinkles. Punch biopsy was performed at BL and day 90; RNA was isolated, gene expression was analyzed, and bulk RNA sequencing performed. Data from both pathways were studied using the Search Tool for Retrieval of Interacting Genes/Proteins and Reactome databases. RESULTS: Analysis at Day 0 and Day 90 showed differing gene regulation for PLLA-SCA and CaHA-R (after accounting for minor differences at BL, p < .05 at Day 90 for 9–12 genes). PLLA-SCA uniquely correlates with genes involved in adipocyte regeneration, while CaHA-R did not affect these genes. Clinically, this could translate to healthy fat replacement with an enhanced effect beyond the improvement of the collagen structure and a longer-lasting effect with PLLA-SCA. Furthermore, the adipokines that appear to be upregulated are regenerative with a positive impact on skin health. CONCLUSION: PLLA-SCA has a novel and unique signature, which supports a potential regenerative mechanism of action through its role in the modulation of adipocyte function.
- 1 November 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 50 (11S) , S166-S171
Comparative Bulk RNA-Seq Analysis of Poly-l-Lactic Acid Versus Calcium Hydroxylapatite Reveals a Novel, Adipocyte-Mediated Regenerative Mechanism of Action Unique to PLLA
BACKGROUND: Injectable biostimulators are widely used to improve facial aging signs. This study was performed to compare the genetic pathways affected by 2 different injectable biostimulators. METHODS: Randomized 13-week study (n = 21) comparing gene expression after poly l-lactic acid (PLLA-SCA) and calcium hydroxylapatite (CaHA-R) injections (baseline [BL] and Day 28) as treatment of nasolabial fold wrinkles. Punch biopsy was performed at BL and day 90; RNA was isolated, gene expression was analyzed, and bulk RNA sequencing performed. Data from both pathways were studied using the Search Tool for Retrieval of Interacting Genes/Proteins and Reactome databases. RESULTS: Analysis at Day 0 and Day 90 showed differing gene regulation for PLLA-SCA and CaHA-R (after accounting for minor differences at BL, p < .05 at Day 90 for 9–12 genes). PLLA-SCA uniquely correlates with genes involved in adipocyte regeneration, while CaHA-R did not affect these genes. Clinically, this could translate to healthy fat replacement with an enhanced effect beyond the improvement of the collagen structure and a longer-lasting effect with PLLA-SCA. Furthermore, the adipokines that appear to be upregulated are regenerative with a positive impact on skin health. CONCLUSION: PLLA-SCA has a novel and unique signature, which supports a potential regenerative mechanism of action through its role in the modulation of adipocyte function.
- Open Access
- 17 October 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 50 (12) , 1137-1142
Midface Projection Using Biostimulatory Poly-l-Lactic Acid Injectable Implant: A Subgroup Analysis of the Cheek Wrinkle Trial
BACKGROUND: Correction of cheek wrinkles using poly-l-lactic acid (PLLA-SCA) was demonstrated in a 12-month study. OBJECTIVE: This analysis assessed change from baseline in lifting effect of PLLA-SCA using a 3D camera to provide additional quantified data. METHODS: Subjects received PLLA-SCA (reconstituted in 8 mL of sterile water + 1 mL of 2% lidocaine) in both cheeks or no treatment (control). Assessments included the Galderma Cheek Wrinkle Scale (GCWS), aesthetic improvement, and 3D photography. In subjects with severe GCWS at baseline, Canfield software analyzed 3D images for change from baseline in midface volume projection and volume change of both cheeks at Month 9. RESULTS: The primary study showed a statistically significant higher at-rest GCWS responder rate at Month 12 for PLLA-SCA, 71.6%, versus control, 26.1% (p < .0001). In this Month 9 analysis, mean midface volume projection demonstrated a positive volume shift for PLLA-SCA (left: 0.45 mm; right: 0.34 mm; n = 46) versus control (left: 0.25 mm; right: −0.01 mm; n = 21). Midface volume and max projection changes for PLLA-SCA were +4.88 mL/+1.62 mm (left), +2.84 mL/+1.12 mm (right) versus +0.26 mL/+0.34 mm (left), +0.68 mL/+0.37 mm (right) for control. CONCLUSION: Poly-l-lactic acid-treatment of subjects with severe GCWS had a clinically meaningful lifting effect in both cheeks (positive volume shift, positive volume change, and max projection) in the midface. Clinical trial registry number: NCT04124692.
- 17 October 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 50 (12) , 1137-1142
Open AccessMidface Projection Using Biostimulatory Poly-l-Lactic Acid Injectable Implant: A Subgroup Analysis of the Cheek Wrinkle Trial
BACKGROUND: Correction of cheek wrinkles using poly-l-lactic acid (PLLA-SCA) was demonstrated in a 12-month study. OBJECTIVE: This analysis assessed change from baseline in lifting effect of PLLA-SCA using a 3D camera to provide additional quantified data. METHODS: Subjects received PLLA-SCA (reconstituted in 8 mL of sterile water + 1 mL of 2% lidocaine) in both cheeks or no treatment (control). Assessments included the Galderma Cheek Wrinkle Scale (GCWS), aesthetic improvement, and 3D photography. In subjects with severe GCWS at baseline, Canfield software analyzed 3D images for change from baseline in midface volume projection and volume change of both cheeks at Month 9. RESULTS: The primary study showed a statistically significant higher at-rest GCWS responder rate at Month 12 for PLLA-SCA, 71.6%, versus control, 26.1% (p < .0001). In this Month 9 analysis, mean midface volume projection demonstrated a positive volume shift for PLLA-SCA (left: 0.45 mm; right: 0.34 mm; n = 46) versus control (left: 0.25 mm; right: −0.01 mm; n = 21). Midface volume and max projection changes for PLLA-SCA were +4.88 mL/+1.62 mm (left), +2.84 mL/+1.12 mm (right) versus +0.26 mL/+0.34 mm (left), +0.68 mL/+0.37 mm (right) for control. CONCLUSION: Poly-l-lactic acid-treatment of subjects with severe GCWS had a clinically meaningful lifting effect in both cheeks (positive volume shift, positive volume change, and max projection) in the midface. Clinical trial registry number: NCT04124692.